Reproductive Endocrinology · Ovarian Hormones

Using anti-Müllerian hormone to predict premature ovarian insufficiency: a retrospective cross-sectional study

Huang Y, Kuang X, Jiangzhou H, Li M, Yang D, Lai D

Published December 4, 2024 Frontiers in Endocrinology, 15, 1454802
DOI 10.3389/fendo.2024.1454802 PMID 39629049 PMC PMC11611575

RRM Academy Synopsis

Low AMH levels are linked to premature ovarian insufficiency

A cross-sectional study of 21,143 Shanghai women aged 18 to 40 found low AMH levels were associated with a sharply increased risk of premature ovarian insufficiency (POI). AMH, anti-Müllerian hormone, is a potential blood marker of ovarian reserve. It predicted POI better than luteinizing hormone (LH) did, with an AUC of 0.900 versus 0.865.

Key Findings

  • Women were grouped by follicle-stimulating hormone (FSH): 16,538 (78.2%) normal, 4,043 (19.1%) elevated, 300 (1.4%) in the POI group and 262 (1.2%) in the premature ovarian failure group.
  • Higher FSH went with significantly lower median AMH (p<0.001). POI risk stayed stable until AMH declined to a threshold, then rose steeply as AMH fell further.
  • Compared with normal AMH, the odds ratio for POI was 66.3 in the lowest AMH group and 4.77 in the middle AMH group.
  • AMH had the best predictive value for POI (AUC 0.900, 95% CI: 0.883-0.918), above LH (AUC 0.865, 95% CI: 0.843-0.883).
  • In decision curve analysis, using AMH to predict POI gave more benefit than the treat-all or treat-none schemes at threshold probabilities under 22%.

Interpretation

This cross-sectional study looked at records from 21,143 women at one Shanghai hospital. Women were grouped by FSH, the marker now used to diagnose POI, so AMH is compared against FSH-based groups. The study excluded women with ovarian surgery, cancer treatment, ovarian tumors, polycystic ovary syndrome (PCOS, also called PMOS) or metabolic disease, isolating the AMH-POI relationship from these other causes. The authors note that very low AMH values are hard to measure precisely and call for more sensitive assays. The findings support prospective longitudinal studies to confirm AMH's predictive role in POI.

RRM Context

The paper lists genetic, autoimmune, treatment-related and unidentified factors as known causes of POI. Restorative reproductive medicine treats a low AMH result as the start of a search for the cause. A cause not yet found is undiagnosed, and finding it is the work that follows.

Abstract

Background

Premature ovarian insufficiency/failure (POI/POF) is a significant issue for women of reproductive age. Anti-Müllerian hormone (AMH) is a potential biomarker of ovarian reserve, but its clinical value in diagnosing and predicting POI/POF remains unclear. This study aimed to analyze the correlation between AMH and basal follicle-stimulating hormone (FSH) levels in women aged 18 to 40 and evaluate AMH's predictive value for POI/POF.

Methods

A total of 21,143 participants aged 18-40 who visited the gynecology department or underwent physical examinations at the International Peace Maternity and Child Health Hospital in Shanghai, China, from July 2016 to June 2021 were enrolled. Demographic information and laboratory test results were collected, including age, FSH, AMH, E2 and test dates. Participants were grouped by FSH and AMH levels, and subgroup analyses were performed to investigate the relationship between these hormones and age. The AMH level associated with POI risk was evaluated using restricted cubic splines (RCS) and logistic regression. Clinical benefit was assessed by decision curve analysis (DCA).

Results

Participants with higher FSH levels had significantly lower median AMH levels and vice versa(p<0.001). At AMH ≥ 0.5 ng/mL, FSH levels were normal or slightly elevated with age. At AMH level below 0.5ng/ml,basal FSH increased significantly with age. At FSH <10 IU/L, AMH levels show a trend of rising and then decreasing with age, reaching a peak at approximately 25 years old and gradually decreasing with age. At FSH ≥10 IU/L, AMH levels show a gradual downward trend with age, and at FSH >40 IU/L, AMH levels remain very low to undetectable values. The RCS showed that the risk of POI/POF in the overall population sharply increased until serum AMH reached a low level (below 0.5ng/ml). DCA showed that a low AMH level had good clinical diagnostic utility in predicting POI/POF.

Conclusion

Our analysis of a large dataset suggests that serum AMH levels are inversely correlated with FSH levels and that AMH is a good predictor of POI until it drops to a low level.

Topics

By this author

Related research

Reproductive Endocrinology › Ovarian Hormones › Estrogen · Diagnostics › Hormone Testing › Serum Panels · Longevity and Reproductive Aging › Reproductive Aging › Ovarian Aging
Yuanxin Huang, Xiaojun Kuang, Huiting Jiangzhou, Meiling Li, Dongjian Yang, Dongmei Lai
Y Huang, X Kuang, H Jiangzhou, M Li, D Yang, D Lai
PMID 39629049 39629049 DOI 10.3389/fendo.2024.1454802 10.3389/fendo.2024.1454802 Huang et al. 2024, Huang 2024